NCT00006041View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

February 29, 2000

Primary Completion Date

February 28, 2002

Study Completion Date

February 28, 2002

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
BIOLOGICAL

MUC1-KLH conjugate vaccine

BIOLOGICAL

MUC1-KLH vaccine/QS21

BIOLOGICAL

QS21

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00006041 - Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | Biotech Hunter | Biotech Hunter